BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28819729)

  • 1. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
    Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
    Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer.
    Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
    Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
    Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
    Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
    Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
    BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.
    Tomasello G; Barni S; Turati L; Ghidini M; Pezzica E; Passalacqua R; Petrelli F
    Clin Colorectal Cancer; 2018 Jun; 17(2):97-103. PubMed ID: 29519711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of poorly differentiated clusters predicts survival in stage II colorectal cancer.
    Ammendola S; Turri G; Marconi I; Burato G; Pecori S; Tomezzoli A; Conti C; Pedrazzani C; Barresi V
    Virchows Arch; 2021 Feb; 478(2):241-248. PubMed ID: 32577812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poorly differentiated clusters (PDC) in colorectal cancer: Does their localization in tumor matter?
    Bertoni L; Barresi V; Bonetti LR; Caramaschi S; Mangogna A; Lionti S; Azzoni P; Carnevale G; Pisciotta A; Salviato T
    Ann Diagn Pathol; 2019 Aug; 41():106-111. PubMed ID: 31233902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters.
    Lionti S; Reggiani Bonetti L; Bettelli S; Spallanzani A; Gelsomino F; Barresi V
    Hum Pathol; 2018 Aug; 78():115-124. PubMed ID: 29715463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters.
    Ueno H; Hase K; Hashiguchi Y; Shimazaki H; Tanaka M; Miyake O; Masaki T; Shimada Y; Kinugasa Y; Mori Y; Kishimoto M; Kameoka S; Sato Y; Matsuda K; Nakadoi K; Shinto E; Nakamura T; Sugihara K
    Am J Surg Pathol; 2014 Feb; 38(2):197-204. PubMed ID: 24418853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
    Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
    Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor-1alpha modulates the down-regulation of the homeodomain protein CDX2 in colorectal cancer.
    Zheng J; Sun X; Wang W; Lu S
    Oncol Rep; 2010 Jul; 24(1):97-104. PubMed ID: 20514449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma.
    Wong NACS; Adamczyk LA; Evans S; Cullen J; Oniscu A; Oien KA
    Histopathology; 2017 Jul; 71(1):34-41. PubMed ID: 28226180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
    Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
    J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.